Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1971 1
1972 3
1975 2
1976 4
1977 1
1978 3
1979 1
1980 1
1981 6
1982 1
1983 1
1984 1
1985 6
1986 4
1987 1
1988 3
1989 1
1990 3
1991 3
1992 3
1993 5
1994 1
1995 3
1996 3
1997 2
1998 3
1999 3
2000 7
2001 2
2002 4
2003 5
2004 6
2005 4
2006 7
2007 6
2009 9
2010 3
2011 6
2012 9
2013 6
2014 7
2015 8
2016 9
2017 13
2018 8
2019 9
2020 6
2021 10
2022 8
2023 4
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

210 results

Results by year

Filters applied: . Clear all
Page 1
Teprotumumab for Thyroid-Associated Ophthalmopathy.
Smith TJ, Kahaly GJ, Ezra DG, Fleming JC, Dailey RA, Tang RA, Harris GJ, Antonelli A, Salvi M, Goldberg RA, Gigantelli JW, Couch SM, Shriver EM, Hayek BR, Hink EM, Woodward RM, Gabriel K, Magni G, Douglas RS. Smith TJ, et al. Among authors: douglas rs. N Engl J Med. 2017 May 4;376(18):1748-1761. doi: 10.1056/NEJMoa1614949. N Engl J Med. 2017. PMID: 28467880 Free PMC article. Clinical Trial.
This response was defined as a reduction of 2 points or more in the Clinical Activity Score (scores range from 0 to 7, with a score of 3 indicating active thyroid-associated ophthalmopathy) and a reduction of 2 mm or more in proptosis at week 24. Secondary end points, measured …
This response was defined as a reduction of 2 points or more in the Clinical Activity Score (scores range from 0 to 7, with a score of 3 ind …
European Position Paper on Rhinosinusitis and Nasal Polyps 2020.
Fokkens WJ, Lund VJ, Hopkins C, Hellings PW, Kern R, Reitsma S, Toppila-Salmi S, Bernal-Sprekelsen M, Mullol J, Alobid I, Terezinha Anselmo-Lima W, Bachert C, Baroody F, von Buchwald C, Cervin A, Cohen N, Constantinidis J, De Gabory L, Desrosiers M, Diamant Z, Douglas RG, Gevaert PH, Hafner A, Harvey RJ, Joos GF, Kalogjera L, Knill A, Kocks JH, Landis BN, Limpens J, Lebeer S, Lourenco O, Meco C, Matricardi PM, O'Mahony L, Philpott CM, Ryan D, Schlosser R, Senior B, Smith TL, Teeling T, Tomazic PV, Wang DY, Wang D, Zhang L, Agius AM, Ahlstrom-Emanuelsson C, Alabri R, Albu S, Alhabash S, Aleksic A, Aloulah M, Al-Qudah M, Alsaleh S, Baban MA, Baudoin T, Balvers T, Battaglia P, Bedoya JD, Beule A, Bofares KM, Braverman I, Brozek-Madry E, Richard B, Callejas C, Carrie S, Caulley L, Chussi D, de Corso E, Coste A, El Hadi U, Elfarouk A, Eloy PH, Farrokhi S, Felisati G, Ferrari MD, Fishchuk R, Grayson W, Goncalves PM, Grdinic B, Grgic V, Hamizan AW, Heinichen JV, Husain S, Ping TI, Ivaska J, Jakimovska F, Jovancevic L, Kakande E, Kamel R, Karpischenko S, Kariyawasam HH, Kawauchi H, Kjeldsen A, Klimek L, Krzeski A, Kopacheva Barsova G, Kim SW, Lal D, Letort JJ, Lopatin A, Mahdjoubi … See abstract for full author list ➔ Fokkens WJ, et al. Among authors: douglas rg. Rhinology. 2020 Feb 20;58(Suppl S29):1-464. doi: 10.4193/Rhin20.600. Rhinology. 2020. PMID: 32077450
The document provides suggestions for future research in this area and offers updated guidance for definitions and outcome measurements in research in different settings. EPOS2020 contains chapters on definitions and classification where we have defined a large number of t …
The document provides suggestions for future research in this area and offers updated guidance for definitions and outcome measurements …
Teprotumumab Efficacy, Safety, and Durability in Longer-Duration Thyroid Eye Disease and Re-treatment: OPTIC-X Study.
Douglas RS, Kahaly GJ, Ugradar S, Elflein H, Ponto KA, Fowler BT, Dailey R, Harris GJ, Schiffman J, Tang R, Wester S, Jain AP, Marcocci C, Marinò M, Antonelli A, Eckstein A, Führer-Sakel D, Salvi M, Sile S, Francis-Sedlak M, Holt RJ, Smith TJ. Douglas RS, et al. Ophthalmology. 2022 Apr;129(4):438-449. doi: 10.1016/j.ophtha.2021.10.017. Epub 2021 Oct 21. Ophthalmology. 2022. PMID: 34688699 Free article. Clinical Trial.
METHODS: OPTIC nonresponders or those who flared (2-mm increase in proptosis, 2-point increase in clinical activity score [CAS], or both) during follow-up were treated for the first time (previous placebo patients) or re-treated with teprotumumab in OPTIC-X with 8 infusions over …
METHODS: OPTIC nonresponders or those who flared (2-mm increase in proptosis, 2-point increase in clinical activity score [CAS], or both) du …
Teprotumumab for patients with active thyroid eye disease: a pooled data analysis, subgroup analyses, and off-treatment follow-up results from two randomised, double-masked, placebo-controlled, multicentre trials.
Kahaly GJ, Douglas RS, Holt RJ, Sile S, Smith TJ. Kahaly GJ, et al. Among authors: douglas rs. Lancet Diabetes Endocrinol. 2021 Jun;9(6):360-372. doi: 10.1016/S2213-8587(21)00056-5. Epub 2021 Apr 15. Lancet Diabetes Endocrinol. 2021. PMID: 33865501 Clinical Trial.
Secondary endpoints at week 24 were the proportion of patients with improved diplopia (1 Bahn-Gorman grade), an overall response (reduction of 2 mm in proptosis and reduction of 2 points in CAS), mean change from baseline in proptosis measurement in the study eye, mean cha …
Secondary endpoints at week 24 were the proportion of patients with improved diplopia (1 Bahn-Gorman grade), an overall response (reduction …
Teprotumumab-Related Adverse Events in Thyroid Eye Disease: A Multicenter Study.
Shah SA, Amarikwa L, Sears CM, Clauss KD, Rajjoub RD, Kang JY, Tamhankar MA, Briceño CA, Harrison AR, Dosiou C, Cockerham KP, Wester ST, Douglas RS, Kossler AL. Shah SA, et al. Among authors: douglas rs. Ophthalmology. 2024 Apr;131(4):458-467. doi: 10.1016/j.ophtha.2023.10.018. Epub 2023 Oct 16. Ophthalmology. 2024. PMID: 37852417
Adverse event metrics were recorded at each visit. MAIN OUTCOME MEASURES: The primary outcomes measure was AE incidence and onset. Secondary outcome measures included AE severity, AE reversibility, AE duration, proptosis response, clinical activity score (CAS …
Adverse event metrics were recorded at each visit. MAIN OUTCOME MEASURES: The primary outcomes measure was AE incidence and on …
Periocular Reconstruction in Patients with Facial Paralysis.
Joseph SS, Joseph AW, Douglas RS, Massry GG. Joseph SS, et al. Among authors: douglas rs. Otolaryngol Clin North Am. 2016 Apr;49(2):475-87. doi: 10.1016/j.otc.2015.10.011. Otolaryngol Clin North Am. 2016. PMID: 27040589 Review.
Patients with expected recovery of facial nerve function may only require temporary and conservative measures to protect the ocular surface. Patients with prolonged or unlikely recovery of facial nerve function benefit from surgical rehabilitation of the periorbital comple …
Patients with expected recovery of facial nerve function may only require temporary and conservative measures to protect the ocular s …
European position paper on diagnostic tools in rhinology.
Rimmer J, Hellings P, Lund VJ, Alobid I, Beale T, Dassi C, Douglas R, Hopkins C, Klimek L, Landis B, Mosges R, Ottaviano G, Psaltis A, Surda P, Tomazic PV, Vent J, Fokkens W. Rimmer J, et al. Among authors: douglas r. Rhinology. 2019 Jul 25;57(Suppl S28):1-41. doi: 10.4193/Rhin19.410. Rhinology. 2019. PMID: 31376816 Review.
Chemosensory (smell and taste) testing is explained, and the available techniques for objective measurement of nasal airflow and patency are reviewed. Prompt and accurate diagnosis allows appropriate management to be initiated; an understanding of the currently available d …
Chemosensory (smell and taste) testing is explained, and the available techniques for objective measurement of nasal airflow and pate …
Teprotumumab for the Treatment of Recalcitrant Thyroid Eye Disease.
Men CJ, Amarikwa L, Pham B, Sears C, Clauss K, Lee BW, Lee WW, Pasol J, Ugradar S, Shinder R, Cockerham K, Wester S, Douglas R, Kossler AL. Men CJ, et al. Among authors: douglas r. Ophthalmic Plast Reconstr Surg. 2023 Nov 16. doi: 10.1097/IOP.0000000000002564. Online ahead of print. Ophthalmic Plast Reconstr Surg. 2023. PMID: 37972960
Only patients who received at least 4 infusions of teprotumumab were included in the analysis. Primary outcome measures comprised proptosis response (2 mm reduction in the study eye without a similar increase in the other eye), clinical activity score (CAS) response (2-poi …
Only patients who received at least 4 infusions of teprotumumab were included in the analysis. Primary outcome measures comprised pro …
Impact of opioid-free analgesia on pain severity and patient satisfaction after discharge from surgery: multispecialty, prospective cohort study in 25 countries.
TASMAN Collaborative. TASMAN Collaborative. Br J Surg. 2024 Jan 3;111(1):znad421. doi: 10.1093/bjs/znad421. Br J Surg. 2024. PMID: 38207169 Free PMC article.
The primary outcomes were patient-reported time in severe pain measured on a numerical analogue scale from 0 to 100% and patient-reported satisfaction with pain relief during the first week following discharge. ...
The primary outcomes were patient-reported time in severe pain measured on a numerical analogue scale from 0 to 100% and patient-repo …
Change in lacrimal gland volume and aqueous tear production following treatment with teprotumumab.
Ugradar S, Zimmerman E, Parunakian E, Kang J, Cockerham K, Douglas RS. Ugradar S, et al. Among authors: douglas rs. Clin Exp Ophthalmol. 2023 May-Jun;51(4):339-348. doi: 10.1111/ceo.14208. Epub 2023 Feb 9. Clin Exp Ophthalmol. 2023. PMID: 36723406
The volume of lacrimal glands and proptosis was calculated using 3D volumetric analysis. Tear production was measured by Schirmer's test and associated symptoms were assessed using the VLSQ-8. ...
The volume of lacrimal glands and proptosis was calculated using 3D volumetric analysis. Tear production was measured by Schirmer's t …
210 results